Fundraising Fox
/Companies
Sign in

PMV Pharma

Cranbury, US · Founded 2013 · 8 known investors

Find your way into PMV Pharma

Sign up to see every warm intro you have to PMV Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the PMV Pharma team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function. The company focuses on treating cancers driven by p53 mutations.

BiotechHealthtech

Founders & leadership

PMV Pharma was founded in 2013 by David H. Mack, Ph.D..

DHDavid H. Mack, Ph.D.
David H. Mack, Ph.D.Founder · President & CEOformerDavid Mack holds a Ph.D. in molecular genetics from the University of Chicago and a B.A. in molecular biology from UC Berkeley. He previously served as a general partner at Alta Partners, co-founded Eos Biotechnology, and held leadership roles at Affymetrix and Cetus, with scientific publications in top-tier journals and multiple issued patents.
DM
David MackNamed on SEC filing
AL
Arnold LevineNamed on SEC filing

Board

PTPeter Thompson
Peter ThompsonBoard directorGeneral Partner at OrbiMed
SW
Steve WinickBoard director
AO
Arnold OronskyBoard director

Investors · 8

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M
OrbiMedreportedNew York · $1M – $75M

How we know: fiercebiotech.com · the VCSheet dataset · Not right? Tell us

Also in the syndicate · 1

Topspin Biotech Fundlead

Funding

SEC filings, press & company announcements

$73.7M disclosed across 1 of 2 rounds · 2017–2020

▶$73.7MraisedMar 2017 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David MackExecutive Officer, Director
  • Peter ThompsonDirector
  • Steve WinickDirector
  • Arnold OronskyDirector
  • Arnold LevineDirector
Offering amount
$73.7M
Amount sold
$73.7M
First sale
Feb 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does PMV Pharma do?
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function. The company focuses on treating cancers driven by p53 mutations.
Who founded PMV Pharma?
PMV Pharma was founded by David H. Mack, Ph.D. in 2013.
Who are PMV Pharma's investors?
PMV Pharma's investors include Avoro Capital Advisors, Nextech Invest, OUP (Osage University Partners), RA Capital, Viking Global, Wellington Management, OrbiMed.
How much funding has PMV Pharma raised?
PMV Pharma has disclosed $73.7M raised across 1 of its 2 known rounds.
Where is PMV Pharma headquartered?
PMV Pharma is headquartered in Cranbury, US.